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Slowed Movement Stopping in 
parkinson’s Disease and focal 
Dystonia is improved by Standard 
treatment
Supriyo choudhury1,6, Akash Roy1,5,6, Banashree Mondal1, Ravi Singh1, Saptak Halder1, 
Koustav chatterjee1, Mark R. Baker2,3,4, Hrishikesh Kumar1* & Stuart N. Baker4*
Patients with Parkinson’s disease and focal dystonia have difficulty in generating and preventing 
movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate 
and stop a movement respectively. We developed a portable device to assess RT and SSRT. This 
incorporated a novel analysis to measure SSRT more efficiently (optimal combination SSRT, ocSSRT). 
After validation ocSSRT was measured in Parkinson’s disease patients without dyskinesia (PD), 
cervical dystonia (CD) and writer’s cramp. We also assessed how ocSSRT responded to L-dopa in PD 
patients and botulinum toxin injections in CD patients. Participants were instructed to release a button 
following a green LED flash on the device. On 25% of trials, a red LED flashed 5–195 ms after the green 
LED; participations were instructed to abort the button release on these trials. ocSSRT and RT were 
significantly prolonged in patients with Parkinson’s disease and focal dystonia (one-way ANOVA 
p < 0.001). Administration of L-dopa significantly improved ocSSRT and RT in PD patients (p < 0.001). 
Administration of botulinum toxin significantly improved ocSSRT, but not RT, in CD patients (p < 0.05). 
ocSSRT is an easily-administered bedside neuro-physiological tool; significantly prolonged ocSSRT is 
associated with PD and focal dystonia.
Patients with movement disorders have deficits in movement production but may also have abnormalities in 
preventing an undesired movement. Some patients with Parkinson’s disease (PD) have trouble terminating their 
gait sequence1, and deficient response inhibition has been reported in a number of other neurological disorders2,3.
Whilst the neural substrate of the stopping process is largely unknown, structures such as the inferior frontal 
gyrus, pre-supplementary motor area, supplementary motor area and basal ganglia have all been implicated4–7.
Reduced activity in the direct and cortico-subthalamic hyper-direct pathways in PD reportedly has a strong asso-
ciation with defective response inhibition7–9.
Investigation of movement inhibition was given a firm quantitative basis following the introduction of the stop 
signal paradigm by Logan and Cowan10. Subjects are asked to respond to a go cue, but to inhibit their responses 
on some trials if a stop cue appears. The paradigm is modelled as a race between a go and stop process which 
occur within the brain. Both processes are initiated by their respective cues, and race each other towards com-
pletion. If the go process finishes first, the response is executed; if the stop process finishes first, the response is 
successfully inhibited. The latency of this stopping process – the stop signal reaction time (SSRT) - is a covert 
expression of stopping ability and can be estimated using the race model. SSRT has been widely used in cogni-
tive neuroscience, psychology and developmental neuroscience11–13. Patients with obsessive compulsive disorder 
and attention deficit hyperactivity disorder have prolonged SSRTs11,14, and SSRT is elevated in young children 
compared to young adults15. In movement disorders patients, SSRT was reported to be uncorrelated with the go 
1Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India. 2Department of Neurology, Royal 
Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne, NE1 4LP, United Kingdom. 3Department of Clinical 
Neurophysiology, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne, NE1 4LP, United Kingdom. 
4Institute of Neuroscience, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 
4HH, United Kingdom. 5Department of Physiology, University of Calcutta, Kolkata, India. 6These authors contributed 
equally: Supriyo Choudhury and Akash Roy. *email: rishi_medicine@yahoo.com; stuart.baker@ncl.ac.uk
open
2Scientific RepoRtS |         (2019) 9:19504  | https://doi.org/10.1038/s41598-019-55321-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
signal reaction time in PD patients2. This suggests that the paradigm may measure stopping independently of any 
coincident bradykinesia.
Motor response inhibition has been previously reported to be deficient in patients with PD, focal hand dysto-
nia and L-dopa induced dyskinesia compared to controls without neurological disorders2,3,16,17. Within the spec-
trum of PD patients, those with freezing of gait have impaired conflict resolution compared to those without this 
sign18. By contrast, SSRT is similar in PD patients with and without impulse control disorder19. Pharmacological 
studies in animals have revealed a role for dopamine and nor-adrenaline in modulating the stop signal response20, 
and consistent with this response inhibition is affected by dopamine receptor polymorphisms in healthy 
humans21. However, studies of PD patients in the ON and OFF states have so far shown conflicting results19,22,23.
In this study, we first introduce a new method to measure SSRT using portable equipment and an improved 
analytical approach. After validating this in healthy subjects, we then apply it to both PD and focal dystonia 
patients. We reveal not only that SSRT is prolonged in these conditions, but that it is improved by treatment. 
Differences between patients and healthy controls were sufficiently robust that measurement of SSRT may be of 
use in pre-screening for movement disorders.
Methods
Population and study procedure. The study was conducted in the movement disorders laboratory 
of a tertiary care referral centre in Eastern India. Ethical approval was obtained from the Institutional Ethics 
Committee of the Institute of Neurosciences, Kolkata; written informed consent was taken from all participants. 
All methods were performed in accordance with the relevant guidelines and regulation of the ethical approval.
The study was conducted in three parts.
Experiment 1: We measured optimal combination SSRT (ocSSRT) and average SSRT (avSSRT, see 
Supplementary Material for definitions) in 20 healthy subjects. Thereafter, the reliability of these measures was 
estimated by a repeat measurement in 14 subjects after a one-month interval; the remaining 6 healthy subjects 
were not available for retest. All healthy participants had no apparent neurological disease, were free from any 
uncontrolled systemic disease, and were not taking any neurotropic medications. None were colour blind by 
self-report and all had normal visual acuity (after correction if necessary). There was no history of substance 
abuse disorder or head injury.
Experiment 2: Measurements of SSRT were made in 30 patients with PD without dyskinesia, 20 patients with 
cervical dystonia (CD) and 10 patients with writer’s cramp (WC), to allow comparison with the healthy control 
data from Exp. 1. Patients with cognitive impairment (Mini Mental State Examination < 24), visual impairment 
or red-green colour blindness were excluded from the cohort24. PD patients were diagnosed using UK Brain Bank 
diagnostic criteria for PD and focal dystonia patients using the MDS consensus for dystonia25,26. The disease 
severity was assessed using standard disease severity scales: for PD, the Movement Disorders Society Unified 
Parkinson’s Disease Rating Scale-III (MDS UPDRS III)27 and Hoehn and Yahr (H&Y) scale28; for CD, the Toronto 
Western Spasmodic Torticollis Rating Scale (TWSTRS)29; for WC, the Writer’s cramp rating scale (WCRS)30. All 
assessments in PD patients were made in the OFF phase, without overnight medication.
Experiment 3: The effects of treatment on SSRT were measured. PD patients (n = 22) were requested to attend 
the clinic without overnight medication (OFF phase) for a baseline SSRT assessment. After this initial measure-
ment, L-dopa was administered (according to the prescribed morning dose, range 100–300 mg, mean 167 mg,). 
The stop signal task was then re-evaluated within one hour (ON phase). For four of these patients, the OFF phase 
measurement used for this experiment was the same as that for Experiment 2. An additional nine patients who 
participated in experiment 2 returned on a separate day to participate in experiment 3, involving repeated meas-
urement of SSRT in ON and OFF phase. Nine further patients participated who had not taken part in Experiment 
3. In 10 CD patients, measures were made before and one month after a botulinum toxin injection in the affected 
muscles. All 10 patients had previously contributed to Experiment 2. The dose and the site of injections were 
selected by one of the authors (HK), who is an experienced movement disorders neurologist.
Hardware. The hardware used to measure SSRT in this study comprised a battery-powered device housed 
within a plastic case, which the subject held comfortably in two hands (see Supplementary Fig. 1A). One red and 
one green LED (5 mm diameter) were positioned on the front of this box; beneath the LEDs was a press button 
(2 cm diameter). Above the LEDs was a four-line LCD screen, which provided a textual status display during 
the test. The device contained a dsPIC30F6012A microcontroller (Microchip Inc) programmed with custom 
firmware written in C using the MPLAB development environment. This controlled the task sequence, measured 
reaction times (1 ms precision) and response probabilities, and computed the results at the end. Numerical values 
for the estimated stop-signal reaction times were then displayed on the LCD screen and were copied down by the 
experimenter into the lab book. The device did not keep a lasting record of the single trial responses.
At the start of our study, some experiments were performed using similar physical hardware, connected to a 
laboratory interface (Micro1401, Cambridge Electronic Design, Cambridge, UK) and computer running Spike2 
software (also Cambridge Electronic Design). The protocol was the same as for the microcontroller-based system, 
but all data were saved as Spike2 files, and subsequent analysis was carried out using scripts written in the Matlab 
environment (Mathworks Inc, Natick, USA).
Test procedure. Participants sat comfortably in a semi-illuminated, quiet room holding the task device. The 
subject initiated a trial by pressing and holding down the response button. The LCD display then indicated the 
instruction ‘Release on green, hold on red’. After a delay (chosen from a uniform random distribution between 1 
and 2.638 s), the green LED illuminated. On 75% of trials, no other LED illuminated, and the subject was required 
to release the button to respond (a GO trial). On 25% of the trials, the red LED illuminated, and the green LED 
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extinguished after a delay (a NOGO trial); the subject was required not to release the button for correct perfor-
mance. Four different stop-signal delays were used: 5, 65, 130 and 195 ms. Trials were presented in blocks of 32, 
with 24 GO trials and 8 NOGO trials (two for each delay) within a block. The order was determined at random 
but adjusted so that a NOGO trial was always preceded and followed by a GO trial. Following button release, there 
was a 1.3 s delay until the next trial started. During a NOGO trial, if the button was not released for 0.7 s after the 
green LED illuminated, this was considered a successful trial; the next trial started after a 2 s delay.
After two blocks of 32 trials, the task was paused for 60 s to allow the subject to rest. Subjects could also initi-
ate a rest at any point by releasing the button, as the next trial did not start until the button was held down. Data 
gathering was stopped after three sets of 64 trials. Subjects were allowed to complete a few trials at the start to 
familiarise themselves with the task; these were discarded and not used for analysis.
Statistical analysis. Mathematical details of our novel analytical approach are described in the 
Supplementary Materials. Analysis resulted in two measures – the average SSRT (avSSRT), which is measured 
as in previous studies, and the optimal combination SSRT (ocSSRT), which uses our novel approach. We also 
measured the median reaction time (RT). Across a population, categorical variables were described with percent-
age and numerical variables using mean (±SD). The unpaired multiple groups were compared using one-way 
ANOVA with post hoc Tukey’s test. The equality of variance between two unpaired groups was compared using 
Levene’s test. The criterion validity and test-retest reliability were assessed using the intra-class correlation coef-
ficient between avSSRT and ocSSRT (considering avSSRT as the gold standard measure). The strength of mean-
ingful correlation was estimated through the correlation coefficient and its level of significance. The homogeneity 
of variance was assessed between test-retest difference of avSSRT and ocSSRT through the Fligner-Killeen test 
(FK test). Cumulative distribution plots of SSRT across subjects were plotted, and from this receiver operating 
characteristic (ROC) curves constructed, which indicate whether a measure might have utility as a diagnostic 
tool. ROC curves were summarized by computing the area under the curve (AUC). An AUC of 0.5 indicates an 
identical distribution of the measure of interest in patients and controls; an AUC of 1.0 occurs if the distributions 
are entirely non-overlapping. Statistical analysis used the SPSS 20 statistical package (SPSS, Chicago, IL, USA) and 
custom-made MATLAB programs.
Results
The baseline demographic and clinical characteristics of subjects are presented in Table 1.
Improved estimation of stop signal reaction time. We first compared the results of measuring SSRT 
using our new statistical approach (ocSSRT) with the more conventional procedure of simply averaging estimates 
made from trials with different stop signal delays (avSSRT). Figure 1A shows as a scatter plot the relation between 
these two measures in 20 healthy volunteers. In this case, for each person the two measures were made from the 
same recorded data. The intra-class correlation coefficient (ICC) between ocSSRT and avSSRT was 0.79 (signifi-
cantly greater than zero, P = 0.001). However, it was noticeable that for some outliers, the two measures were quite 
different. For example, for one subject the avSSRT was 210 ms, whereas the ocSSRT was 171 ms. Further inves-
tigation revealed that this subject stopped his response perfectly for both the 5 ms and 65 ms stop signal delays, 
which led to an overestimate of SSRT at those delays. This inevitably produced a high value in the simple average 
(avSSRT). By contrast, the Bayesian approach naturally assigned high uncertainty to the measures at these delays, 
and gave little weight to them in the combination to generate ocSSRT. This illustrates the advantage of ocSSRT, 
which weights the different SSRT estimates by their reliability.
We then investigated the reliability of the two measures, by retesting 14 of the same subjects after one month. The 
ICC for avSSRT between the two repeats was 0.68, whereas it was 0.99 for ocSSRT (both significantly different from 
zero, p = 0.0001). Figure 1B presents the distribution of the difference in each parameter from the first to second 
measurement. The test-retest difference in the avSSRT was more variable than for ocSSRT (p = 0.009, FK test).
Parkinson’s Disease
Subset of Parkinson’s Disease 
patients who underwent 







Number 30 22 20 10 20
Male (%) 63% 64% 70% 100% 75%
Age in years 
(Mean ± SD) 59 ± 14.1** 66.5 ± 6.5** 43.3 ± 11.9 NS 53 ± 4.1 NS 37.4 ± 13.3
Disease Duration in 
years (Mean ± SD) 6.5 ± 4.3 6.2 ± 2.2 5.4 ± 2.3 3.2 ± 1.7 NA
Severity scale 
(Mean ± SD)
UPDRS III (OFF) 30.7 ± 10.6
H&Y (OFF) 3.2 ± 1.05
UPDRS III (OFF) 25.9 ± 6.8




5.29 ± 1.25 NA
Table 1. Demographic and disease characteristics of movement disorders patients and healthy controls. The 
motor severity of Parkinson’s disease was estimated using Movement Disorders Society- Unified Parkinson’s 
Disease Rating Scale-III (MDS UPDRS III). The severity of cervical dystonia was estimated by Toronto Western 
Spasmodic Torticollis Rating Scale (TWSTRS) – pain and disability score. The severity of Writer’s cramp 
was estimated via the Writer’s cramp rating scale (WCRS) total score. Ages for the patient groups have been 
compared with the healthy participant cohort; **P < 0.001; NS, not significantly different (P > 0.05).
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Comparison of results in movement disorders patients with healthy controls. Figure 2A pre-
sents the results for ocSSRT, and also the RT measured from the GO trials, for healthy controls and the vari-
ous movement disorder patient groups. As might be expected, reaction times were significantly faster for the 
healthy controls than each patient group (controls, 350 ± 50 ms; PD OFF, 491 ± 88 ms; CD, 563 ± 118 ms; WC, 
481 ± 60 ms; p = 0.0001 for comparison of each patient group with controls). In addition, the patients showed 
increased ocSSRT compared to the controls (controls, 238 ± 34 ms; PD OFF, 362 ± 62 ms; CD, 373 ± 76 ms; WC, 
306 ± 25 ms; p = 0.0001, comparison of each patient group with controls). The standard deviation of ocSSRT was 
greater in CD but not in PD OFF and WC compared to healthy (controls, 34.1 ms; PD OFF, 62.1 ms; CD, 76.3 ms; 
WC, 25.3 ms; p = 0.07, 0.01, 0.43 respectively for PD, CD and WC). The extent of slowing of ocSSRT was not the 
same across the three movement disorders examined, with WC showing significantly shorter ocSSRT compared 
to PD (in OFF) and CD patients (p = 0.009 and p = 0.001 respectively). Notably, the RT (PD OFF 464 ± 52 ms, 
p < 0.001) and ocSSRT (PD OFF 368 ± 72 ms, p < 0.001) were also significantly prolonged in a subgroup of eight 
early PD patients (H&Y stage 1 and 2) compared to healthy controls. As expected, there were differences between 
this early subgroup and the remaining PD patients of our cohort in disease duration (4.8 ± 2.8 years vs. 8.4 ± 4.2 
years, mean ± SD p = 0.03), UPDRS III score (20.7 ± 2.3 vs 30.4 ± 6.1, p = 0.005) and daily dose of levodopa 
(433 ± 44 ms vs 590 ± 105 mg, p = 0.001). The difference of RT and ocSSRT for PD patients persisted after adjust-
ment for age as a covariant (p < 0.001).
In none of the patient groups investigated was there a significant correlation between RT and ocSSRT 
(Pearson’s correlation coefficient r: PD, r = −0.097, p = 0.61; CD, r = 0.137, p = 0.57; WC, r = −0.039, p = 0.94), 
although in healthy controls this correlation showed a non-significant trend (r = −0.426, p = 0.061).We 
observed no correlation with RT of TWSTRS (r = −0.379, p = 0.12), UPDRS III (r = −0.185, p = 0.42) or WCRS 
(r = −0.154, p = 0.74) in the respective patient groups. ocSSRT did not show a correlation with the severity of 
PD measured using either H&Y staging (r = −0.213, p = 0.26) or UPDRS III (r = 0.209, p = 0.42). Similarly, the 
severity of CD as estimated by TWSTRS was not correlated with ocSSRT (r = −0.03; p = 0.90).
Improvement following standard treatment. Having demonstrated that these measurements are dif-
ferent in movement disorders patients, it was then of interest to determine whether they could be improved by 
standard treatments. Figure 2B shows a comparison of measures recorded in a sub-set of 22 PD patients in both 
the OFF and ON phase. RT was significantly decreased from 548 ms to 494 ms by taking L-dopa. ocSSRT was also 
significantly decreased, from 382 ms to 313 ms (both p = 0.0001). As might be expected, patients with the most 
prolonged ocSSRT in the OFF phase showed a trend for the greatest improvements from OFF to ON, although 
this just failed to reach significance (correlation coefficient between OFF ocSSRT and change in ocSSRT was 
0.378, p = 0.083).By contrast, there was no relationship between the OFF RT and the change in ocSSRT from OFF 
to ON (correlation coefficient 0.117, p = 0.61).
Figure 1. Validity and reliability of optimum combination stop signal reaction time (ocSSRT) compared 
to average stop signal reaction time (avSSRT). (A) Scatter plot showing association between avSSRT and 
ocSSRT. The intra-class correlation coefficient (ICC) of ocSSRT and avSSRT in 20 healthy volunteers was 0.79 
(p = 0.001). The line of best fit (dotted line) shows a linear relationship between two measures. (B) Box and 
whisker plot compares the median difference and inter-quartile range (IQR, a measure of dispersion) of ocSSRT 
and avSSRT between two sets (baseline test and retest) of stop signal tasks (with an interval of one month) 
completed in 14 healthy individuals. The graph shows that test-retest difference of ocSSRT was significantly 
lower than avSSRT (Wilcoxon signed ranks test, p = 0.048). The dispersion of test-retest difference was 
significantly more for avSSRT (Fligner-Killeen test; p = 0.009). There is therefore an increased variability and 
reduced precision of avSSRT compared to ocSSRT.
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One possible confounding factor in this result is that the PD patients were tested twice on the same day, which 
could have resulted in a learning effect. To check whether this was likely, we carried out further measurements 
in ten healthy subjects, who were retested twice on the same day with an interval between tests of just one hour. 
We found no significant differences between either RT (mean 358 ms vs 357 ms for first and second measure-
ment respectively, p = 0.96) or ocSSRT (231 ms vs 230 ms, p = 0.95). We therefore conclude that changes seen in 
Parkinson’s patients were most likely due to an action of their dopaminergic medication, and not a learning effect 
caused by retesting on the same day.
Figure 2C compares measurements made in CD patients before, and one month after, their dystonia was 
treated by botulinum toxin injection. RT was unchanged by this treatment (before, 572 ms; after, 558 ms; p = 0.25), 
whereas there was a significant reduction in ocSSRT (before, 357 ms; after, 287 ms; p = 0.006).
Separation of groups on the basis of response measures. Figure 2A revealed a significant difference 
of RT and ocSSRT between movement disorders patients and healthy controls at a population level. It is of interest 
to know whether this difference was sufficiently robust to allow reliable diagnosis of individuals. This is explored 
in Figs. 3 and 4, which presents cumulative probability distribution plots (Figs. 3A,C,E and 4A,C,E) for each 
movement disorder group in comparison to healthy controls. These are then used to compile the corresponding 
receiver operating characteristic (ROC) curves (Figs. 3B,D,F and 4B,D,F). For PD, CD and WC patients, there 
was a clear separation in the distribution of RT and ocSSRT from healthy controls. This led to ROC curves which 
lay far from the identity line (dotted in Figs. 3B,D,F and 4B,D,F). The area under the ROC curve for ocSSRT was 
0.903, 0.903 and 0.898 for PD, CD and WC patients respectively. For comparison, the area under the ROC curve 
for RT was 0.908, 0.904 and 0.885 and for avSSRT (data not illustrated) was 0.947, 0.925 and 0.935 for PD, CD 
and WC patients respectively. All of these values were significantly higher than 0.5 which would be expected for 
entirely overlapping distributions (p = 0.0001, Monte Carlo test).
As noted above, although WC patients had a significantly slower ocSSRT than healthy subjects, the extent 
of this slowing was smaller than for either PD or CD groups. ROC analysis showed that WC patients could be 
significantly discriminated from PD and CD patients on the basis of ocSSRT (area under ROC curve 0.825 and 
0.85 respectively; both significantly different from 0.5, p = 0.0001, Monte Carlo test). By contrast, WC patients 
could not be significantly discriminated from PD or CD patients on the basis of RT (area under the curve 0.650 
and 0.713) or avSSRT (area under the curve 0.668 and 0.690).
Discussion
Optimal combination SSRT as a measure of the stopping process. In this study we introduced 
ocSSRT as an improved method for estimating SSRT. Most of the literature has reported results based on the 
avSSRT. The ocSSRT was in agreement with the avSSRT when measured from the same experiment, thus val-
idating this newly-developed statistical measure. However, the test-retest reliability for a group of healthy par-
ticipants who performed the trial on two separate days over an interval of one month showed a much stronger 
agreement between ocSSRT compared with avSSRT. Either SSRT measure could therefore be used interchange-
ably in cross-sectional studies where the aim is to compare stopping process among various groups, although 
the decreased variability of ocSSRT will increase the statistical power of comparisons and there would be more 
chance for the differences to reach significance with fewer subjects. For a prospective study, ocSSRT would also 
have advantages over avSSRT due to its higher test-retest reliability.
Figure 2. ocSSRT and reaction time (RT) in patients with movement disorders and after treatment. (A) ocSSRT 
and reaction time (RT) were significantly prolonged in patients with movement disorders compared to healthy 
participants. Overall differences among groups were compared by one-way ANOVA (p < 0.001). (B) ocSSRT 
and RT of patients with Parkinson’s disease reduce significantly from baseline (OFF state) to one hour after 
the administration of L-Dopa (ON state) (p < 0.001, paired sample t-test). (C) ocSSRT reduces significantly 
in patients with cervical dystonia from baseline to one-month post-treatment with botulinum toxin injection 
(p < 0.05, paired sample t-test).
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Prolonged SSRT in PD patients. In our study we observed that both RT and ocSSRT were significantly 
prolonged in PD compared to healthy volunteers. Interestingly, in healthy controls RT and ocSSRT showed a 
trend towards positive correlation, whereas these measures were uncorrelated in PD. In agreement with our find-
ings, Gauggel et al. compared the stop signal task in 32 patients with PD and 31 orthopaedic controls2. The extent 
of bradykinesia was unrelated to SSRT in PD, but in the orthopaedic controls initiation speed could explain some 
of the variance in time taken to inhibit action. It is likely that some common processes influence both response 
speed and stopping, and that these vary across healthy individuals to generate a weak correlation. However, the 
pathological processes which lead to slowing in RT and SSRT appear separable.
Prolonged SSRT in focal dystonia patients. We also observed prolonged SSRT in CD and WC patients 
compared to healthy participants. The result in WC is in agreement with previous work, which demonstrated a 
lower rate of response inhibition in patients with task specific focal hand dystonia3. It is intriguing that we addi-
tionally found elevated SSRT in CD, as our task involved releasing a button with the hand as a response; the hand 
was not affected by the dystonia in these individuals. The size of the increase in SSRT was actually larger in CD 
than in WC (Fig. 3A), emphasising that congruence between the muscles used to respond in the task and those 
involved in the dystonia was not an important factor. Even in WC, our results were surprising as the response 
movement required by the task did not induce dystonia, which was specific to writing. It seems likely that these 
patients have a more general underlying pathology in networks for response inhibition, which is unrelated to the 
nature of the focal presentation of the dystonia itself.
One factor to be considered is that both SSRT and RT might be affected by cognitive decline. In this context 
our findings in focal dystonia are interesting, since these disorders do not have a cognitive component, unlike PD. 
In addition, SSRT and RT changes were seen in early stage PD patients, where cognitive decline should be low. 
It seems therefore that the rises in SSRT and RT reflect, at least in part, a genuine component of the movement 
disorder, rather than being simply related to cognitive changes.
Figure 3. The cumulative probability and receiver operating characteristic (ROC) curves for RT in healthy 
controls and patients with movement disorders. (A,C,E) Cumulative probability distributions of RT in patients 
with Parkinson’s disease (PD), cervical dystonia (CD) and writer’s cramp (WC) (thick line) and healthy controls 
(thin line). (B,D,F) ROC plots derived from the cumulative probability distributions in (A,C,E) confirming 
that RT can effectively separate healthy controls from PD, CD and WC patients. Dotted diagonal line indicates 
expected result if RT did not discriminate the groups.
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SSRT is not a predictor of disease severity. Although all groups of movement disorders patients tested 
showed prolonged SSRT, within a particular disease group there was no correlation between SSRT and clini-
cal measures of disease severity. Previous studies also failed to find a relation between the prolonged SSRT of 
PD patients and global measures of cognitive impairment or severity of disease2,31. By contrast, a more specific 
assessment of the severity of levodopa-induced dyskinesia in PD patients does show a correlation with SSRT32. 
The disease severity demonstrated no significant correlation with RT. This is expected as the major deficit in PD 
is bradykinesia and not the prolongation of reaction time9. It is likely that a multitude of changes to cortical and 
sub-cortical networks result from disease pathology and attempts at compensation to restore function. Global 
disease severity probably results from a myriad of different interactions and impairments, with many possible 
routes to generate a similar level of impairment. Only a sub-set of these networks will affect response inhibition 
as measured by SSRT; these may overlap with the circuits responsible for dyskinesia32. Interestingly, the ocSSRT 
was significantly prolonged even in a sub-set of patients with early stage of disease, suggesting that ocSSRT might 
be developed as an early disease marker.
Standard treatments partially normalise SSRT. Although SSRT did not correlate with disease severity, 
when patients were treated SSRT was reduced. In PD patients, the SSRT was significantly reduced by levodopa 
treatment. This is in agreement with past work which showed an improvement in response inhibition in the ON 
phase22, although two previous studies failed to find a decrease specifically in SSRT with dopaminergic medica-
tions19,23. It is possible that our improved approach to estimation of SSRT allowed us to detect a relation, which 
could otherwise be masked by measurement variability.
It is perhaps not unexpected that treatment with a centrally-acting drug such as levodopa could modulate 
response inhibition. Interestingly, the patients with more prolonged OFF ocSSRT (unlike with more prolonged 
OFF RT) demonstrated a positive correlation with change in ocSSRT after levodopa administration. This differ-
ential correlation could suggest that RT and ocSSRT may be measuring underlying processes which are differently 
affected by the disease.
Figure 4. The cumulative probability and receiver operating characteristic (ROC) curves for ocSSRT in 
healthy controls and patients with movement disorders. (A,C,E) Cumulative probability distributions of 
ocSSRT in patients with Parkinson’s disease (PD), cervical dystonia (CD) and writer’s cramp (WC) (thick line) 
and healthy controls (thin line). (B,D,F) ROC plots derived from the cumulative probability distributions in 
(A,C,E) confirming that ocSSRT can effectively separate healthy controls from PD, CD and WC patients. Dotted 
diagonal line indicates expected result if ocSSRT did not discriminate the groups.
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More unexpected was our finding that treatment of dystonia with botulinum toxin injections into the dystonic 
muscles also reduced SSRT. A direct central effect of the toxin is unlikely, as we expect minimal passage across the 
blood brain barrier. It is possible that the reduced SSRT is simply a consequence of the reduction of symptoms. 
Abnormal movements or posturing generated by CD could have engaged the patient in compensatory move-
ments, thereby diverting attention from the stop signal task during the pre-treatment assessment. After effectively 
treating the dystonic condition with botulinum toxin, the cause of this inattention would be removed, allowing 
the patient to perform the task without diversion. However, against this explanation, the reaction time was not 
improved by botulinum toxin injection; this should be affected similarly to SSRT if the underlying cause is simply 
a reduction in distracting dystonia. This might suggest that RT and ocSSRT measure different underlying pro-
cesses which respond to therapy in a different way. We suggest that the most likely cause for the observed SSRT 
reduction is that toxin therapy produced a chronic alteration of sensory input to the brain, which modulated 
the abnormal central network. In support of this idea, the long latency trans-cortical reflex in idiopathic focal 
dystonia is reduced significantly following botulinum toxin therapy33, and cortico-spinal plasticity is changed34.
conclusions
In this study, we have developed and validated an improved measure of SSRT and shown that implementing 
this in a portable device can deliver a simple and reliable test suitable for clinical use. Measures in patients were 
not just significantly different from healthy controls at a group level, but also showed sufficiently robust differ-
ences to allow accurate separation of individuals. Furthermore, WC patients could be separated from PD and CD 
patients only on the basis of our improved ocSSRT measure. The sub-set of patients with early symptoms of PD 
also demonstrated an abnormally prolonged ocSSRT. This suggests that SSRT could find utility as a marker for 
enhanced diagnosis (e.g. rapid throughput pre-screening) and to assess the response to treatments.
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